1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Anika Therapeutics, Inc.

Anika Therapeutics, Inc.

ANIK
Anika Therapeutics, Inc.US flagNASDAQ Global Select
14.74
USD
+0.02
- -
196.12MMarket Cap
Anika Therapeutics, Inc.
ANIK
(NASDAQ Global Select)

Recent

price

14.74

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.4
4.96
5.38
5.33
7.19
6.23
7.04
7.78
7.31
8.12
9.17
10.26
7.82
8.24
8.14
7.87
8.22
Revenue per Share
0.34
0.65
0.89
1.46
2.61
2.06
2.22
2.18
1.3
1.93
-1.69
0.29
-1.02
-5.64
-3.83
-0.76
-0.78
Basic EPS, GAAP
0.4
0.67
0.68
1.76
2.62
2.05
0.71
2.18
2.1
2.42
0.8
0.23
-0.21
-0.49
-0.2
0.3
0.07
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
2.05
2.63
3.48
4.74
7.16
9.09
11.47
13.7
15.12
17.39
15.58
15.67
14.48
8.75
4.88
4.25
3.95
Book Value per Share
3.99
4.8
6
7.61
10.55
12.84
13.99
16.78
17.07
19.34
12.15
13.67
13.98
13.79
9.81
9.33
8.79
Tangible Book Value per Share
13
13
13
14
15
15
15
15
14
14
14
14
15
15
15
14
14
Basic Weighted Avg Shares
56
65
71
75
106
93
103
113
106
115
130
148
114
121
120
113
116
Sales/Revenue/Turnover
13.57
21.56
31.19
43.05
58.19
51.76
48.95
40.32
20.6
29.88
-11.09
-12.5
3.22
0.7
-4.25
-9.8
-10.54
Operating Margin (%)
3
4
5
5
5
4
4
4
6
6
13
14
14
14
8
6
6
Depreciation Expense
4
8
12
21
38
31
33
32
19
27
-24
4
-15
-83
-56
-11
-11
Net Income, GAAP
41.22
38.58
39.79
36.65
37.7
36.26
36.02
31.14
19.33
24.72
- -
- -
49.12
208.97
- -
- -
- -
Effective Tax Rate (%)
7.77
13.07
16.48
27.4
36.29
33.07
31.48
28.05
17.74
23.73
-18.38
2.8
-13.05
-68.44
-47.02
-9.64
-9.52
Profit Margin (%)
37
50
63
85
132
159
162
193
192
218
141
139
142
132
90
81
73
Working Capital
11
10
8
- -
- -
- -
- -
- -
- -
21
21
19
29
26
24
24
24
LT Debt
85
95
109
136
178
211
223
263
264
288
272
287
286
212
154
143
134
Total Equity
4.56
8.41
11.85
16.01
24.4
15.62
14.8
13.01
6.7
9.01
- -
- -
0.6
-0.33
- -
- -
- -
Return on Invested Capital (%)
11.86
20.08
23.2
33.6
44.61
25.54
21.4
17.29
8.96
11.18
- -
- -
-6.08
-41.57
- -
- -
- -
Return on Capital (%)
18.16
28.08
29.2
36.46
44.61
25.54
21.4
17.29
8.96
11.72
-10.27
1.85
-6.81
-48.76
-56.38
-16.39
-18.02
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
2
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
23
24
24
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
13
Market Capitalization
135
138
205

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
102
103
94
Cash, Cash Equivalents & STI
58
57
41
Accounts Receivable, Net
22
24
26
Inventories
16
19
23
Total Current Liabilities
19
22
21
Payables & Accruals
8
9
9
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-2.73%
-11.02%
-6.83%
Free Cash Flow
-35.93%
-87.97%
-248.82%
Net Income, GAAP
-41.34%
-46.56%
-80.7%
Sales/Revenue/Turnover
2.61%
-2.04%
-5.91%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
29
31
30
-1
120
2025
26
28
28
31
113
2026
30
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.31
-0.01
-2.03
-1.5
-3.83
2025
-0.34
-0.28
-0.16
0.02
-0.76
2026
-0.37
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PAVmed Inc. (PAVMW)
C-Rad AB (publ) (CRAD-B.ST)
Urologix, Inc. (ULGX)
Double Medical Technology Inc. (002901.SZ)
Butterfly Network, Inc. (BFLY-WT)
Medicalgorithmics S.A. (MDG.WA)
Business
Anika Therapeutics, Inc. is a global joint preservation company specializing in early intervention orthopedic care. The company develops, manufactures, and commercializes therapeutic products designed for osteoarthritis (OA) pain management, regenerative solutions, and sports medicine. Its core product portfolio is based on its proprietary hyaluronic acid (HA) technology platform, including OA pain management injectables such as Monovisc and Orthovisc, and the next-generation single-injection product Cingal, which combines cross-linked HA with a steroid. Anika’s regenerative solutions include the Integrity Implant System, an HA-based scaffold for rotator cuff and tendon repairs, as well as other orthopedic implants and instruments like the X-Twist Fixation System. The company also markets advanced shoulder arthroplasty systems supported by preoperative planning software. Founded in 1996 and headquartered in Bedford, Massachusetts, Anika operates globally with a significant presence in the United States and international markets. The company targets orthopedic surgeons, sports medicine specialists, and healthcare providers focusing on joint preservation and repair. Recent major changes include the strategic divestiture of the Arthrosurface business in October 2024 and the completed sale of Parcus Medical to Medacta Group SA in March 2025, enabling Anika to concentrate fully on its core hyaluronic acid technology and expanding Regenerative Solutions portfolio. Additionally, in 2024, Anika launched several new products including the Integrity Implant System and X-Twist Fixation System, and advanced its FDA regulatory filings for Hyalofast, a proprietary HA scaffold for cartilage repair with U.S. market launch anticipated by 2026. The company’s strategic focus is on profitable growth through its HA-driven OA pain management products and high growth regenerative solutions. Anika Therapeutics leverages a technology-driven approach within the healthcare equipment and supplies industry, dedicating resources to innovation in minimally invasive orthopedic products and early intervention treatments, positioning itself as a leader in joint preservation and restoring active mobility worldwide.

Company News

MCPAPIChat

  • globenewswire.com

    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • seekingalpha.com

    Bullish On Anika Therapeutics's Pullback As Integrity Scales

  • seekingalpha.com

    Anika Therapeutics, Inc. (ANIK) Q1 2026 Earnings Call Transcript

  • globenewswire.com

    Anika Reports First Quarter 2026 Financial Results

  • globenewswire.com

    Anika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026

  • gurufocus.com

    Is Anika Therapeutics Inc (ANIK) a Bargain After 3.1% Drop? GF Value Says Undervalued

  • globenewswire.com

    Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • benzinga.com

    Top 2 Health Care Stocks That May Crash This Quarter

  • seekingalpha.com

    Anika Therapeutics, Inc. (ANIK) Q4 2025 Earnings Call Transcript

  • zacks.com

    Anika Therapeutics (ANIK) Q4 Earnings and Revenues Beat Estimates

  • globenewswire.com

    Anika Reports Fourth Quarter and Full Year 2025 Financial Results

  • defenseworld.net

    Anika Therapeutics (NASDAQ:ANIK) Stock Passes Above 200 Day Moving Average – Here’s What Happened

  • globenewswire.com

    Anika To Present at the Canaccord Genuity 2026 Musculoskeletal Conference

  • globenewswire.com

    Anika to Issue Fourth Quarter and Year-End 2025 Financial Results on Thursday, February 26, 2026

  • globenewswire.com

    ANIKA INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C. Reminds Anika Therapeutics Investors to Contact the Firm Regarding the Ongoing Investigation on Behalf of Anika Stockholders

  • businesswire.com

    ANIK INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Anika Therapeutics, Inc.

  • businesswire.com

    ANIK Investigation: Investors Encouraged to Contact Kirby McInerney LLP

  • globenewswire.com

    Anika Therapeutics, Inc. INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors ANIK

  • defenseworld.net

    Connor Clark & Lunn Investment Management Ltd. Acquires 8,573 Shares of Anika Therapeutics Inc. $ANIK

  • seekingalpha.com

    Anika Therapeutics, Inc. (ANIK) Q3 2025 Earnings Call Transcript